ACOG:TSV-Alpha Cognition Inc (CAD)

COMMON STOCK | Biotechnology | TSV

Last Closing Price

CAD 0.30

Change

-0.01 (-3.23)%

Market Cap

CAD 0.02B

Volume

7.17K

Avg Analyst Target

CAD 3.00 (+900.00%)

Avg User Target

CAD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ACOG Stock Forecast & Price:
Based on the Alpha Cognition Inc stock forecasts from 1 analysts, the average analyst target price for Alpha Cognition Inc is CAD 3.00 over the next 12 months. Alpha Cognition Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Alpha Cognition Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Alpha Cognition Inc’s stock price was CAD 0.30. Alpha Cognition Inc’s stock price has changed by -18.92% over the past week, -40.00% over the past month and -70.30% over the last year.

About Alpha Cognition Inc (ACOG:CA:TSV)

Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type an ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ARCH:CA Arch Biopartners Inc

-0.11 (-3.73%)

CAD0.18B 284.00 7,292.87
IPA:CA Immunoprecise Antibodies Ltd

N/A

CAD0.11B 2.50 137.07
NVH:CA Novoheart Holdings Inc

N/A

CAD0.10B N/A N/A
NGEN:CA NervGen Pharma Corp

-0.08 (-4.44%)

CAD0.10B N/A N/A
MIR:CA MedMira Inc

N/A

CAD0.08B N/A 579.63
GSD:CA Devonian Health Group Inc

-0.03 (-6.82%)

CAD0.06B N/A N/A
COV:CA Covalon Technologies Ltd.

+0.01 (+0.44%)

CAD0.06B 37.50 -13.26
VXL:CA Vaxil Bio Ltd

-0.01 (-25.00%)

CAD0.06B N/A N/A
CZO:CA Ceapro

-0.02 (-2.86%)

CAD0.05B 9.71 5.12
SBM:CA Sirona Biochem Corp

N/A

CAD0.05B N/A N/A

ETFs Containing ACOG:CA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -72.22% 25% F 14% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -72.22% 25% F 14% F
Trailing 12 Months  
Capital Gain -77.44% 21% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -77.44% 21% F 9% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -16.37% 25% F 22% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.37% 25% F 22% F
Risk Return Profile  
Volatility (Standard Deviation) 25.11% 96% A 83% B
Risk Adjusted Return -65.21% 18% F 19% F
Market Capitalization 0.02B 61% D- 63% D
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 8.74 36% F 20% F
Price / Cash Flow Ratio -2.07 26% F 21% F
EV/EBITDA -1.62 85% B 56% F
Management Effectiveness  
Return on Equity -696.94% 20% F 5% F
Return on Invested Capital -173.49% 29% F 11% F
Return on Assets -160.88% 19% F 8% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.63 42% F 39% F
Short Percent 0.39% 6% F 9% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.